This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article in the ARCHIVES by Weintraub and colleagues¹ contends that fluctuations in the levels of lipids should be taken into account when monitoring postmenopausal women receiving combined sequential estrogen replacement therapy (ERT) for hypercholesterolemia. They justify the importance of such monitoring with the statement that "ERT is associated with a 50% reduction in the incidence of coronary artery disease(CAD)."¹ While this statement might have been well founded at the time of submission of the paper, new scientific evidence has surfaced since then that sheds a different light on the role of estrogen in the treatment of ischemic heart disease. The Heart and Estrogen/ Progestin Replacement Study (HERS) trial recently published in JAMA² has shown under randomized placebo controlled double-blind conditions that ERT did not decrease the incidence of coronary heart disease events (nonfatal myocardial infarction or coronary heart disease death) in a large number of postmenopausal women followed for . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?